Literature DB >> 12153518

Maternal and newborn immunization with a human immunodeficiency virus-1 immunogen in a rodent model.

Ronald B Moss1, Jay R Savary, Jocelyn P Diveley, Fred Jensen, Dennis J Carlo.   

Abstract

We examined immunization with an inactivated, gp120-depleted human immunodeficiency virus (HIV) antigen in incomplete Freund's adjuvant (IFA), also containing a sequence of immunostimulatory (ISS) DNA, during the last trimester of pregnancy and neonatally in a rat model. Pregnant rats were immunized in the third trimester and their litters were immunized during the newborn period. In addition, litters of rats from non-immunized mothers were immunized during the neonatal period. As another control, pregnant rats were immunized and their litters analysed. Supernants from peripheral blood mononuclear cells (PBMCs) were assayed from newborns at 4 weeks of age for HIV-specific interferon-gamma (IFN-gamma), HIV-specific regulated on activation, normal, T-cell expressed, and secreted (RANTES), and serum for p24 antigen-specific immunoglobulin G (IgG) production. In the animals whose pregnant mothers were immunized and were also immunized during the neonatal period, we observed HIV-specific IFN-gamma production and HIV-specific RANTES production, but weak p24 IgG antibody production. Animals immunized only during the neonatal period developed the highest levels of HIV-specific IFN-gamma production, but somewhat lower levels of HIV-specific RANTES and p24 IgG antibody production. The group of animals whose mothers had received immunizations during the last trimester of pregnancy, but were not immunized during the neonatal period, developed the strongest p24 IgG antibody levels, but little or undetectable HIV-specific IFN-gamma or RANTES production. Neonatal immunization resulted primarily in cell-mediated immune responses, while animals born to mothers who were immunized during the last trimester had primarily an antibody-mediated immune response. Immunization of pregnant animals followed by neonatal immunization resulted in a mixed cell-mediated/antibody type profile in the neonatal animal. Future studies should provide insights into neonatal immunity and potential vaccine approaches to prevent neonatal infection and perinatal transmission.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12153518      PMCID: PMC1782757          DOI: 10.1046/j.1365-2567.2002.01464.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  19 in total

1.  Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status.

Authors:  A Garzino-Demo; R B Moss; J B Margolick; F Cleghorn; A Sill; W A Blattner; F Cocchi; D J Carlo; A L DeVico; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides.

Authors:  R B Moss; J Diveley; F Jensen; D J Carlo
Journal:  Vaccine       Date:  2000-01-06       Impact factor: 3.641

Review 3.  CpG DNA as a Th1 trigger.

Authors:  K Heeg; S Zimmermann
Journal:  Int Arch Allergy Immunol       Date:  2000-02       Impact factor: 2.749

4.  Transplacental genetic immunization after intravenous delivery of plasmid DNA to pregnant mice.

Authors:  K Okuda; K Q Xin; A Haruki; S Kawamoto; Y Kojima; F Hirahara; H Okada; D Klinman; K Hamajima
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

5.  Immunostimulatory bacterial DNA sequences activate dendritic cells and promote priming and differentiation of CD8+ T cells.

Authors:  R E Tascon; S Ragno; D B Lowrie; M J Colston
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

6.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

7.  HIV-Specific CD4(+) and CD8(+) immune responses are generated with a gp120-depleted, whole-killed HIV-1 immunogen with CpG immunostimulatory sequences of DNA.

Authors:  R B Moss; J Diveley; F C Jensen; E Gouveia; J Savary; D J Carlo
Journal:  J Interferon Cytokine Res       Date:  2000-12       Impact factor: 2.607

8.  Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA.

Authors:  R B Moss; J Diveley; F C Jensen; E Gouveia; D J Carlo
Journal:  J Hum Virol       Date:  2001 Jan-Feb

9.  Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators.

Authors:  W Borkowsky; D Wara; T Fenton; J McNamara; M Kang; L Mofenson; E McFarland; C Cunningham; A M Duliege; D Francis; Y Bryson; S Burchett; S A Spector; L M Frenkel; S Starr; R Van Dyke; E Jimenez
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

10.  Cytokine patterns during progression to AIDS in children with perinatal HIV infection.

Authors:  E Hyjek; H W Lischner; T Hyslop; J Bartkowiak; M Kubin; G Trinchieri; D Kozbor
Journal:  J Immunol       Date:  1995-10-15       Impact factor: 5.422

View more
  2 in total

Review 1.  Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.

Authors:  Bassel Akache; Felicity C Stark; Gerard Agbayani; Tyler M Renner; Michael J McCluskie
Journal:  Methods Mol Biol       Date:  2022

2.  HLA-G DNA sequence variants and risk of perinatal HIV-1 transmission.

Authors:  Felix O Aikhionbare; K Kumaresan; Falah Shamsa; Vincent C Bond
Journal:  AIDS Res Ther       Date:  2006-10-23       Impact factor: 2.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.